Transregulation of memory CD8 T-cell proliferation by IL-15Ralpha+ bone marrow-derived cells - PubMed (original) (raw)
. 2004 Feb 1;103(3):988-94.
doi: 10.1182/blood-2003-08-2814. Epub 2003 Sep 25.
Affiliations
- PMID: 14512307
- DOI: 10.1182/blood-2003-08-2814
Free article
Transregulation of memory CD8 T-cell proliferation by IL-15Ralpha+ bone marrow-derived cells
Kimberly S Schluns et al. Blood. 2004.
Free article
Abstract
Interleukin 15 (IL-15) and the IL-15 receptor alpha (IL-15Ralpha) chain are both required for the basal proliferation of memory CD8 T cells, but which cell types are required to express IL-15 or IL-15Ralpha to mediate this proliferation is not known. Using bone marrow (BM) chimeras, we showed that virus-specific CD8 memory T-cell proliferation was driven by IL-15 produced by either BM-derived or parenchymal cells. Experiments using mixed BM chimeras showed that IL-15Ralpha expression by memory CD8 T cells was not required for their division. In addition, wild-type memory CD8 T cells did not divide after transfer into IL-15Ralpha(-/-) mice. Further analyses demonstrated that IL-15Ralpha(+) BM-derived cells were crucial in driving memory CD8 T-cell division in the spleen while both parenchymal and BM-derived cells promoted memory cell division in the lung. Proliferation in response to soluble IL-15 in vivo required expression of IL-15Ralpha by opposing cells and IL-15Rbeta by CD8 memory cells, indicating that IL-15 interacted directly with the T cells. These results indicate that transpresentation of IL-15 by IL-15Ralpha on BM-derived cells mediates the basal proliferation of memory CD8 T cells.
Similar articles
- Coordinate expression and trans presentation of interleukin (IL)-15Ralpha and IL-15 supports natural killer cell and memory CD8+ T cell homeostasis.
Burkett PR, Koka R, Chien M, Chai S, Boone DL, Ma A. Burkett PR, et al. J Exp Med. 2004 Oct 4;200(7):825-34. doi: 10.1084/jem.20041389. Epub 2004 Sep 27. J Exp Med. 2004. PMID: 15452177 Free PMC article. - Cutting edge: transpresentation of IL-15 by bone marrow-derived cells necessitates expression of IL-15 and IL-15R alpha by the same cells.
Sandau MM, Schluns KS, Lefrancois L, Jameson SC. Sandau MM, et al. J Immunol. 2004 Dec 1;173(11):6537-41. doi: 10.4049/jimmunol.173.11.6537. J Immunol. 2004. PMID: 15557143 - T cell-independent interleukin 15Ralpha signals are required for bystander proliferation.
Lodolce JP, Burkett PR, Boone DL, Chien M, Ma A. Lodolce JP, et al. J Exp Med. 2001 Oct 15;194(8):1187-94. doi: 10.1084/jem.194.8.1187. J Exp Med. 2001. PMID: 11602647 Free PMC article. - IL-15 and IL-15Ralpha in CD4+T cell immunity.
Van Belle T, Grooten J. Van Belle T, et al. Arch Immunol Ther Exp (Warsz). 2005 Mar-Apr;53(2):115-26. Arch Immunol Ther Exp (Warsz). 2005. PMID: 15928580 Review. - Increasing the biological activity of IL-2 and IL-15 through complexing with anti-IL-2 mAbs and IL-15Rα-Fc chimera.
Votavova P, Tomala J, Kovar M. Votavova P, et al. Immunol Lett. 2014 May-Jun;159(1-2):1-10. doi: 10.1016/j.imlet.2014.01.017. Epub 2014 Feb 7. Immunol Lett. 2014. PMID: 24512738 Review.
Cited by
- Recent advances in CD8+ T cell-based immune therapies for HIV cure.
Arenas VR, Rugeles MT, Perdomo-Celis F, Taborda N. Arenas VR, et al. Heliyon. 2023 Jun 20;9(6):e17481. doi: 10.1016/j.heliyon.2023.e17481. eCollection 2023 Jun. Heliyon. 2023. PMID: 37441388 Free PMC article. Review. - Exploiting an Interleukin-15 Heterodimeric Agonist (N803) for Effective Immunotherapy of Solid Malignancies.
Lui G, Minnar CM, Soon-Shiong P, Schlom J, Gameiro SR. Lui G, et al. Cells. 2023 Jun 12;12(12):1611. doi: 10.3390/cells12121611. Cells. 2023. PMID: 37371081 Free PMC article. Review. - Responsiveness to interleukin-15 therapy is shared between tissue-resident and circulating memory CD8+ T cell subsets.
Jarjour NN, Wanhainen KM, Peng C, Gavil NV, Maurice NJ, Borges da Silva H, Martinez RJ, Dalzell TS, Huggins MA, Masopust D, Hamilton SE, Jameson SC. Jarjour NN, et al. Proc Natl Acad Sci U S A. 2022 Oct 25;119(43):e2209021119. doi: 10.1073/pnas.2209021119. Epub 2022 Oct 19. Proc Natl Acad Sci U S A. 2022. PMID: 36260745 Free PMC article. - Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors.
Conlon K, Watson DC, Waldmann TA, Valentin A, Bergamaschi C, Felber BK, Peer CJ, Figg WD, Potter EL, Roederer M, McNeel DG, Thompson JA, Gupta S, Leidner R, Wang-Gillam A, Parikh NS, Long D, Kurtulus S, Ho Lee L, Chowdhury NR, Bender F, Pavlakis GN. Conlon K, et al. J Immunother Cancer. 2021 Nov;9(11):e003388. doi: 10.1136/jitc-2021-003388. J Immunother Cancer. 2021. PMID: 34799399 Free PMC article. Clinical Trial. - Short-course IL-15 given as a continuous infusion led to a massive expansion of effective NK cells: implications for combination therapy with antitumor antibodies.
Dubois SP, Miljkovic MD, Fleisher TA, Pittaluga S, Hsu-Albert J, Bryant BR, Petrus MN, Perera LP, Müller JR, Shih JH, Waldmann TA, Conlon KC. Dubois SP, et al. J Immunother Cancer. 2021 Apr;9(4):e002193. doi: 10.1136/jitc-2020-002193. J Immunother Cancer. 2021. PMID: 33883258 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials